Inhibikase Therapeutics (NASDAQ:IKT) Earns “Sell (D-)” Rating from Weiss Ratings

Inhibikase Therapeutics (NASDAQ:IKT)‘s stock had its “sell (d-)” rating reiterated by equities research analysts at Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.

Separately, Wall Street Zen upgraded shares of Inhibikase Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 20th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has a consensus rating of “Sell”.

Inhibikase Therapeutics Stock Performance

NASDAQ IKT opened at $1.66 on Wednesday. Inhibikase Therapeutics has a 12-month low of $1.15 and a 12-month high of $4.20.

Inhibikase Therapeutics Company Profile

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.